Your browser doesn't support javascript.
loading
Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test.
Mirghani, Haïtham; Casiraghi, Odile; Guerlain, Joanne; Amen, Furrat; He, Ming-Xiao; Ma, Xiao-Jun; Luo, Yuling; Mourareau, Céline; Drusch, Françoise; Lakdhar, Aïcha Ben; Melkane, Antoine; St Guily, Lacau; Badoual, Cécile; Scoazec, Jean Yves; Borget, Isabelle; Aupérin, Anne; Dalstein, Veronique; Vielh, Philippe.
Afiliação
  • Mirghani H; Department of Otolaryngology - Head and Neck Surgery, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France. Electronic address: haitham.mirghani@gustaveroussy.fr.
  • Casiraghi O; Department of Biopathology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.
  • Guerlain J; Department of Otolaryngology - Head and Neck Surgery, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.
  • Amen F; Department of Otolaryngology, Peterborough City Hospital and Addenbrooke's Hospital, Cambridge, UK.
  • He MX; Advanced Cell Diagnostics, 3960 Point Eden Way, Hayward, CA 94545, USA.
  • Ma XJ; Advanced Cell Diagnostics, 3960 Point Eden Way, Hayward, CA 94545, USA.
  • Luo Y; Advanced Cell Diagnostics, 3960 Point Eden Way, Hayward, CA 94545, USA.
  • Mourareau C; INSERM UMR-S 903, SFR CAP-Santé FED 4231, Université de Reims Champagne-Ardenne, F-51100 Reims, France.
  • Drusch F; Biobank, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.
  • Lakdhar AB; Department of Biopathology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.
  • Melkane A; Department of Otolaryngology - Head and Neck Surgery, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.
  • St Guily L; Department of Otolaryngology-Head and Neck Surgery, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, France.
  • Badoual C; Department of Pathology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, France.
  • Scoazec JY; Department of Biopathology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France; Biobank, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France; Laboratory of Translational Research, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.
  • Borget I; Department of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.
  • Aupérin A; Department of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.
  • Dalstein V; INSERM UMR-S 903, SFR CAP-Santé FED 4231, Université de Reims Champagne-Ardenne, F-51100 Reims, France.
  • Vielh P; Department of Biopathology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France; Laboratory of Translational Research, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.
Oral Oncol ; 62: 101-108, 2016 11.
Article em En | MEDLINE | ID: mdl-27865361
BACKGROUND: Accurate identification of HPV-driven oropharyngeal cancer (OPC) is a major issue and none of the current diagnostic approaches is ideal. An in situ hybridization (ISH) assay that detects high-risk HPV E6/E7 mRNA, called the RNAscope HPV-test, has been recently developed. Studies have suggested that this assay may become a standard to define HPV-status. METHODS: To further assess this test, we compared its performance against the strategies that are used in routine clinical practice: p16 immunohistochemistry (IHC) as a single test and algorithms combining p16-IHC with HPV-DNA identification by PCR (algorithm-1) or ISH (algorithm-2). RESULTS: 105 OPC specimens were analyzed. The prevalence of HPV-positive samples varied considerably: 67% for p16-IHC, 54% for algorithm-1, 61% for algorithm-2 and 59% for the RNAscope HPV-test. Discrepancies between the RNAscope HPV-test and p16-IHC, algorithm-1 and 2 were noted in respectively 13.3%, 13.1%, and 8.6%. The 4 diagnostic strategies were able to identify 2 groups with different prognosis according to HPV-status, as expected. However, the greater survival differential was observed with the RNAscope HPV-test [HR: 0.19, 95% confidence interval (CI), 0.07-0.51, p=0.001] closely followed by algorithm-1 (HR: 0.23, 95% CI, 0.08-0.66, p=0.006) and algorithm-2 (HR: 0.26, 95% CI, 0.1-0.65, p=0.004). In contrast, a weaker association was found when p16-IHC was used as a single test (HR: 0.33, 95% CI, 0.13-0.81, p=0.02). CONCLUSIONS: Our findings suggest that the RNAscope HPV-test and p16-based algorithms perform better that p16 alone to identify OPC that are truly driven by HPV-infection. The RNAscope HPV-test has the advantage of being a single test.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Algoritmos / Carcinoma de Células Escamosas / Neoplasias Orofaríngeas / Alphapapillomavirus Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Oral Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Algoritmos / Carcinoma de Células Escamosas / Neoplasias Orofaríngeas / Alphapapillomavirus Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Oral Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article